ES2976169T3 - Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante - Google Patents

Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante Download PDF

Info

Publication number
ES2976169T3
ES2976169T3 ES20216368T ES20216368T ES2976169T3 ES 2976169 T3 ES2976169 T3 ES 2976169T3 ES 20216368 T ES20216368 T ES 20216368T ES 20216368 T ES20216368 T ES 20216368T ES 2976169 T3 ES2976169 T3 ES 2976169T3
Authority
ES
Spain
Prior art keywords
rvwf
fviii
composition
administered
rfviii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20216368T
Other languages
English (en)
Spanish (es)
Inventor
Friedrich Scheiflinger
Peter Turecek
Bruce Ewenstein
Wing Yen Wong
Tobias M Suiter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2976169T3 publication Critical patent/ES2976169T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES20216368T 2011-06-10 2012-06-11 Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante Active ES2976169T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161495884P 2011-06-10 2011-06-10
US201161511901P 2011-07-26 2011-07-26
US201161523790P 2011-08-15 2011-08-15

Publications (1)

Publication Number Publication Date
ES2976169T3 true ES2976169T3 (es) 2024-07-24

Family

ID=46321496

Family Applications (3)

Application Number Title Priority Date Filing Date
ES20216368T Active ES2976169T3 (es) 2011-06-10 2012-06-11 Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante
ES12728919.7T Active ES2682249T3 (es) 2011-06-10 2012-06-11 Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante
ES18173179T Active ES2860450T3 (es) 2011-06-10 2012-06-11 Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES12728919.7T Active ES2682249T3 (es) 2011-06-10 2012-06-11 Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante
ES18173179T Active ES2860450T3 (es) 2011-06-10 2012-06-11 Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante

Country Status (23)

Country Link
US (3) US9272021B2 (enExample)
EP (3) EP3412305B1 (enExample)
JP (3) JP6347468B2 (enExample)
KR (3) KR101969515B1 (enExample)
CN (3) CN108210889A (enExample)
AR (1) AR086904A1 (enExample)
AU (5) AU2012267458A1 (enExample)
CA (1) CA2838845C (enExample)
DK (3) DK3412305T3 (enExample)
ES (3) ES2976169T3 (enExample)
FI (1) FI3858375T3 (enExample)
HK (1) HK1257436A1 (enExample)
HR (1) HRP20180962T1 (enExample)
HU (1) HUE039317T2 (enExample)
LT (1) LT2717905T (enExample)
MX (2) MX350582B (enExample)
PL (3) PL2717905T3 (enExample)
PT (3) PT3412305T (enExample)
RU (2) RU2628537C2 (enExample)
SG (2) SG10202002591QA (enExample)
SI (1) SI2717905T1 (enExample)
TR (1) TR201808823T4 (enExample)
WO (1) WO2012171031A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3412305T3 (da) * 2011-06-10 2021-03-01 Baxalta GmbH Behandling af koagulationssygdom ved administration af rekombinant vwf
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
EP2796145B1 (en) * 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
FR3034669B1 (fr) * 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
CA3020346A1 (en) 2016-04-15 2017-10-19 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regimen
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
KR102788331B1 (ko) 2017-07-07 2025-03-27 다케다 야쿠힌 고교 가부시키가이샤 재조합 vwf의 투여에 의해 대기 수술을 받은 중증 폰 빌레브란트 병을 가지고 있는 환자의 치료
EP4424366A3 (en) 2017-07-07 2024-12-04 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
EP3749696A1 (en) 2018-02-06 2020-12-16 Ablynx N.V. Methods of treating initial episode of ttp with immunoglobulin single variable domains
IL277464B1 (en) * 2018-03-21 2026-04-01 Baxalta Inc Separation of VWF and VWF propeptide using chromatographic methods
EA202192140A1 (ru) * 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
CN114929260A (zh) * 2019-09-11 2022-08-19 武田药品工业株式会社 与冯维勒布兰德因子和补体c1q的复合物相关的治疗方法
CN115335074A (zh) * 2020-02-04 2022-11-11 武田药品工业株式会社 通过施用重组vwf来治疗患有重度冯维勒布兰德病的患者的月经过多
TW202237149A (zh) * 2020-11-24 2022-10-01 美商邦德治療公司 用於治療出血性障礙之組成物及方法
WO2024124136A1 (en) * 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4638028A (en) 1985-04-08 1987-01-20 Goodyear Tire & Rubber Company Rubber polymerases and methods for their production and use
EP0218692A4 (en) 1985-04-11 1988-03-22 Childrens Medical Center VON WILLEBRAND FACTOR.
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6864403B1 (en) 1998-10-15 2005-03-08 E. I. Du Pont De Nemours And Company Plant protein disulfide isomerases
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
CN101163506B (zh) * 2004-12-27 2012-09-26 巴克斯特国际公司 聚合物-von Willebrand因子偶联物
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
JP2010529155A (ja) * 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのｖｗｆ安定化ｆｖｉｉｉ製剤及びｆｖｉｉｉなしのｖｗｆ製剤の使用
KR20100095441A (ko) 2007-11-09 2010-08-30 백스터 인터내셔널 인코포레이티드 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법
JP2009127455A (ja) 2007-11-20 2009-06-11 Bando Kiko Co Ltd 往復動エンジン
SG187410A1 (en) * 2007-12-28 2013-02-28 Baxter Int Recombinant vwf formulations
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
PL2291523T3 (pl) * 2008-06-24 2015-05-29 Csl Behring Gmbh Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo
EP2349314B1 (en) * 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
AU2010279463A1 (en) * 2009-08-04 2012-03-01 Baxter Healthcare S.A. Transgenic mouse knockout for FVIII and VWF - model of hemophilia A
WO2012006594A1 (en) 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant adamts13 in cell culture
US20120006800A1 (en) 2010-07-09 2012-01-12 Illinois Tool Works Inc. Weld bead feature communication systems and devices
DK3412305T3 (da) * 2011-06-10 2021-03-01 Baxalta GmbH Behandling af koagulationssygdom ved administration af rekombinant vwf

Also Published As

Publication number Publication date
PT2717905T (pt) 2018-07-02
KR20200091476A (ko) 2020-07-30
KR101969515B1 (ko) 2019-04-16
PL3858375T3 (pl) 2024-05-20
EP2717905A1 (en) 2014-04-16
AU2012267458A1 (en) 2014-01-09
AU2016202299B2 (en) 2017-07-20
LT2717905T (lt) 2018-10-10
JP2017019788A (ja) 2017-01-26
CA2838845A1 (en) 2012-12-13
AU2022201518A1 (en) 2022-03-24
EP3412305B1 (en) 2021-01-06
JP6347468B2 (ja) 2018-06-27
KR20190041032A (ko) 2019-04-19
RU2019103386A (ru) 2020-08-07
SG10202002591QA (en) 2020-05-28
US20120316116A1 (en) 2012-12-13
JP2019048892A (ja) 2019-03-28
DK2717905T3 (en) 2018-07-02
US20250387455A1 (en) 2025-12-25
PL3412305T3 (pl) 2021-05-31
AR086904A1 (es) 2014-01-29
ES2682249T3 (es) 2018-09-19
EP2717905B1 (en) 2018-05-23
AU2017206235A1 (en) 2017-08-03
SG10201604684WA (en) 2016-07-28
TR201808823T4 (tr) 2018-07-23
AU2016202299A1 (en) 2016-05-05
JP6527114B2 (ja) 2019-06-05
MX2020000083A (es) 2020-08-06
EP3858375B1 (en) 2024-03-20
AU2022201518B2 (en) 2025-07-03
PT3412305T (pt) 2021-01-29
DK3412305T3 (da) 2021-03-01
BR112013031795A2 (pt) 2016-12-20
HRP20180962T1 (hr) 2018-10-19
CA2838845C (en) 2019-08-06
CN103732244A (zh) 2014-04-16
RU2680402C2 (ru) 2019-02-21
ES2860450T3 (es) 2021-10-05
KR102319868B1 (ko) 2021-11-01
EP3858375A1 (en) 2021-08-04
MX350582B (es) 2017-09-11
US9272021B2 (en) 2016-03-01
US20160184403A1 (en) 2016-06-30
RU2014100107A (ru) 2015-07-20
AU2017206235B2 (en) 2019-10-17
MX2013014543A (es) 2014-06-11
SI2717905T1 (sl) 2018-09-28
PL2717905T3 (pl) 2018-10-31
DK3858375T3 (da) 2024-04-15
HUE039317T2 (hu) 2018-12-28
FI3858375T3 (fi) 2024-04-17
RU2017102679A (ru) 2018-12-19
CN107412743A (zh) 2017-12-01
RU2017102679A3 (enExample) 2018-12-19
JP2014516088A (ja) 2014-07-07
EP3412305A1 (en) 2018-12-12
CN108210889A (zh) 2018-06-29
PT3858375T (pt) 2024-04-18
AU2020200026A1 (en) 2020-01-30
HK1257436A1 (zh) 2019-10-18
KR20140039285A (ko) 2014-04-01
RU2628537C2 (ru) 2017-08-18
NZ618790A (en) 2015-07-31
CN107412743B (zh) 2021-07-02
RU2019103386A3 (enExample) 2022-01-24
WO2012171031A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
ES2976169T3 (es) Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante
JP7641327B2 (ja) 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
ES2788870T3 (es) Formulación de factor VIII
ES3004108T3 (en) Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
BR112013031795B1 (pt) Uso de fator de von willebrand recombinante (rvwf)
RU2787855C2 (ru) Лечение нарушений свертываемости крови путем введения рекомбинантного фактора виллебранда
HK40056758A (en) Treatment of coagulation disease by administration of recombinant vwf
HK40056758B (en) Treatment of coagulation disease by administration of recombinant vwf
HK40001633A (en) Treatment of coagulation disease by administration of recombinant vwf
JP2023514541A (ja) 組換えｖｗｆの投与による重症のフォンヴィレブランド病患者における過多月経の治療
HK40001633B (en) Treatment of coagulation disease by administration of recombinant vwf
HK1196768A (en) Treatment of coagulation disease by administration of recombinant vwf
HK1196768B (en) Treatment of coagulation disease by administration of recombinant vwf